
	Webcast of the analyst conference on the occasion of the publication of the 6 months 2010 financial results on Thursday, August 5, 2010 at 10.00 am CEST
	MediGene AG Reports Financial Results for First Six Months of 2010: Continuing Increase in Total Revenue, Significant Reduction of Loss more

	MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties more

	MediGene reports additional phase II results of EndoTAG(TM)-1 for the treatment of triple receptor-negative breast cancer more

	MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea more

Drugs for the market

MediGene's vision is the expansion of the potentials in medicine
by means of utilizing biotechnology in a responsible manner.
We apply state-of-the-art technologies in the development of
innovative drugs for the treatment of cancer and autoimmune
diseases.